Champions Oncology Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Champions Oncology Inc in the first quarter 2026?
Champions Oncology Inc achieved a return on average equity (ROE) of 0.94 % in its first quarter 2026, this is above CSBR's average return on equity of -182.81%.
Champions Oncology Inc shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $4 million

While the company's net income was fading, Champions Oncology Inc was able to improve its ROE compared to the fourth quarter 2026.

Within the Biotechnology & Pharmaceuticals industry 20 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 3766 to 3911.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jul 31 2026) I. Quarter	(Apr 30 2026) IV. Quarter	(Jan 31 2026) III. Quarter	(Oct 31 2025) II. Quarter	(Jul 31 2025) I. Quarter
Y / Y Equity Change	26.06 %	7.85 %	-	521.29 %	-
Y / Y Net Income Change	-	-	-	-67.45 %	-
Net Income (TTM) in Millions	0	0	-2	2	3
Return On Equity (TTM)	0.94 %	-0.03 %	-61.2 %	100.89 %	191.98 %
CSBR's Total Ranking	# 3911	# 3766	# 2962	# 124	# 68
Equity (TTM) in Millions	4	4	4	4	4
Seq. Equity Change	9.64 %	7.85 %	-10.85 %	19.59 %	-6.2 %
Seq. Net Income Change	-	-	-	-	-

Back to CSBR Management Effectiveness >> CSBR's 5 Years Annual ROE >> Compare CSBR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 21
Sector	# 211
Overall	# 3911

Return On Equity Statistics
High	Average	Low
847.79 %	-182.81 %	-1414.96 %
(Apr 30 2025)		(Oct 31 2017)

CSBR Annual Return On Equity	(Apr 30 2026) 2026	(Apr 30 2025) 2025	(Apr 30 2024) 2024	(Apr 30 2023) 2023	(Apr 30 2022) 2022
Total Equity in Millions	4	4	-2	5	9
Y / Y Equity Change	7.85 %	-	-	-49.03 %	22.46 %
Net Income in Millions	-1	5	-7	-5	1
Y / Y Net Income Change	-	-	-	-	51.38 %
Return On Equity	-28.88 %	124.63 %	-	-115.08 %	6.02 %

Back to CSBR Management Effectiveness >> CSBR's 5 Years Annual ROE >> Compare CSBR ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CSBR's' Return on Equity at Yahoo Finance
CSBR's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CSBR's Competitors
Subscribers only: Roe for Champions Oncology Inc 's Suppliers
Subscribers only: Return On Equity for CSBR's Customers

Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector	ROE
Cormedix Inc	2.18 %
Atricure Inc	2.14 %
Pacira Biosciences inc	2.13 %
Warby Parker Inc	2.06 %
Repligen Corp	1.98 %
Arvinas Inc	1.91 %
Waters Corporation	1.88 %
Omada Health Inc	1.84 %
Radnet Inc	1.42 %
Icu Medical Inc	1.41 %
Biomarin Pharmaceutical Inc	1.18 %
Staar Surgical Co	1.08 %
Champions Oncology Inc	0.94 %
Delcath Systems Inc	0.46 %

Date modified: 2026-09-13T23:25:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.